Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 3, 2010, Pages 537-544

  Berti, Valentina ^a   Polito, Cristina ^a   Ramat, Silvia ^a   Vanzi, Eleonora ^a   De Cristofaro, Maria Teresa ^a   Pellicanò, Giannantonio ^a   Mungai, Francesco ^a   Marini, Paolo ^a   Formiconi, Andreas Robert ^a   Sorbi, Sandro ^a   Pupi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Basal ganglia; FDG; FP CIT; Parkinson's disease

Indexed keywords

FLUORODEOXYGLUCOSE F 18; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL) NORTROPANE; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALGORITHMS; BRAIN; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEOSTRIATUM; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 77949264922     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1259-x     Document Type: Article

References (50)

1. A Hughes SE Daniel L Kilford AJ Lees 1992 Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 181 184 10.1136/jnnp.55.3.181 1:STN:280:DyaK383is1Omsg%3D%3D 1564476
2. JM Fearnley AJ Lees 1991 Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 2283 2301 10.1093/brain/114.5.2283 1933245
3. JP Seibyl 2003 Imaging studies in movement disorders Semin Nucl Med 33 105 113 10.1053/snuc.2003.127303 12756643 (Pubitemid 36577053)
4. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism Eur J Nucl Med 28 266 272 10.1007/s002590000460 1:CAS:528:DC%2BD3MXitFeiur0%3D 11315592
5. J Spiegel G Hellwig S Samnick W Jost MO Mollers K Fassbender, et al. 2007 Striatal FP-CIT uptake differs in subtypes of early Parkinson's disease J Neural Transm 114 331 335 10.1007/s00702-006-0518-2 1:STN:280: DC%2BD2s7htlWrsA%3D%3D 16715205 (Pubitemid 46328648)
6. V Marshall D Grosset 2003 Role of dopamine transporter imaging in routine clinical practice Mov Disord 18 1415 1423 10.1002/mds.10592 14673877 (Pubitemid 38035363)
7. E Bezard CE Gross JM Brotchie 2003 Presymptomatic compensation in Parkinson's disease is not dopamine-mediated Trends Neurosci 26 215 221 10.1016/S0166-2236(03)00038-9 1:CAS:528:DC%2BD3sXis12nsbw%3D 12689773 (Pubitemid 36412004)
8. H Braak K Del Tredici H Bratzke J Hamm-Clement D Sandmann-Keil U Rüb 2002 Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) J Neurol 249 Suppl 3 III/1-5 12528692
9. JA Obeso MC Rodriguez-Oroz JL Lanciego M Rodriguez Diaz 2004 How does Parkinson's disease begin? The role of compensatory mechanisms Trends Neurosci 27 125 127 10.1016/j.tins.2003.12.006 1:CAS:528:DC%2BD2cXhsV2msrg%3D 15036875 (Pubitemid 38251511)
10. T Eckert A Barnes V Dhawan S Frucht MF Gordon AS Feigin, et al. 2005 FDG PET in the differential diagnosis of parkinsonian disorders NeuroImage 26 912 921 10.1016/j.neuroimage.2005.03.012 15955501 (Pubitemid 40825033)
11. D Eidelberg JR Moeller V Dhawan P Spetsieris S Takikawa T Ishikawa, et al. 1994 The metabolic topography of parkinsonism J Cereb Blood Flow Metab 14 783 801 1:STN:280:DyaK2czkt1CgtA%3D%3D 8063874
12. M Fukuda C Edwards D Eidelberg 2001 Functional brain networks in Parkinson's disease Parkinsonism and Related Disorders 8 91 94 10.1016/S1353-8020(01)00022-0 1:STN:280:DC%2BD383ovFWqsQ%3D%3D 11489673 (Pubitemid 32728021)
13. C Huang C Tang A Feigin M Lesser Y Ma M Pourfar, et al. 2007 Changes in network activity with the progression of Parkinson's disease Brain 130 1834 1846 10.1093/brain/awm086 17470495 (Pubitemid 47343798)
14. A Nagano-Saito T Kato Y Arahata Y Washimi A Nakamura Y Abe, et al. 2004 Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies NeuroImage 22 553 561 10.1016/j.neuroimage.2004.01.030 15193583 (Pubitemid 38759417)
15. G Tissingh J Booij P Bergmans A Winogrodzka A Janssen E Van Royen, et al. 1998 Iodine-123-N-fluoropropyl-2 - carbomethoxy-3-(4-iodophenyl)tropane SPECT in healthy controls and early stage, drug-naive Parkinson's disease J Nucl Med 39 1143 1148 1:CAS:528:DyaK1cXkvVWlsbs%3D 9669384
16. RB Innis VJ Cunningham J Delforge M Fujita A Gjedde RN Gunn, et al. 2007 Consensus nomenclature for in vivo imaging of reversibly binding radioligands J Cereb Blood Flow Metab 27 1533 1539 10.1038/sj.jcbfm.9600493 1:CAS:528:DC%2BD2sXptlSqtrc%3D 17519979 (Pubitemid 47301451)
17. E Vanzi MT De Cristofaro S Ramat B Sotgia M Mascalchi AR Formiconi 2007 A direct ROI quantification method for inherent PVE correction: accuracy assessment in striatal SPECT measurements Eur J Nucl Med Mol Imaging 34 1480 1489 10.1007/s00259-007-0404-7 17390134 (Pubitemid 47312589)
18. 123I-FP- CIT in de novo idiopathic Parkinson's disease patients Eur J Nucl Med Mol Imaging 35 2220 2226 10.1007/s00259-008-0872-4 18649079
19. S Fahn D Oakes I Shoulson K Kieburtz A Rudolph A Lang, et al. 2004 Levodopa and the progression of Parkinson's disease N Engl J Med 351 2498 2508 10.1056/NEJMoa033447 1:CAS:528:DC%2BD2cXhtVGksbnE 15590952 (Pubitemid 39603163)
20. MM Hoehn MD Yahr 1967 Parkinsonism: onset, progression and mortality Neurology 17 427 442 1:STN:280:DyaF2s7jvFSgsg%3D%3D 6067254
21. Fahn S, Elton RL. and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent development in Parkinson's disease. Florham Park: Macmillan Healthcare information; 1987. pp. 153-64.
22. HM Hudson RS Larkin 1994 Accelerated image reconstruction using ordered subsets of projection data IEEE Transm Med Imaging 13 601 609 10.1109/42.363108 1:STN:280:DC%2BD1c%2FmsFCkuw%3D%3D
23. L Chang 1987 A method for attenuation correction in computed tomography IEEE TransNuclSci 25 638 664
24. KS Arun TS Huang S Blostein 1987 Least-squares of two 3d point sets IEEE Trans Pattern Anal Mach Intell 9 698 700 10.1109/TPAMI.1987.4767965
25. AR Formiconi 1993 Least squares algorithm for region of interest evaluation in emission tomography IEEE Trans Med Imag 12 90 100 10.1109/42.222672 1:STN:280:DC%2BD1c%2FmsFegug%3D%3D
26. AR Formiconi A Passeri P Calvini 1999 Theoretical determination of the collimator geometrical transfer function for the reconstruction of SPECT data IEEE Trans Nucl Sci 46 1075 1080 10.1109/23.790830 (Pubitemid 30507001)
27. IU Isaias R Benti R Cilia M Canesi G Marotta P Gerundini, et al. 2007 [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset NeuroReport 18 1499 1502 10.1097/WNR.0b013e3282ef69f9 17712282 (Pubitemid 47295953)
28. K Worsley S Marrett P Neelin A Vanda K Friston A Evans 1996 A unified statistical approach for determining significant signals in images of cerebral activation Human Brain Mapping 4 58 73 10.1002/(SICI)1097-0193(1996)4:1<58:: AID-HBM4>3.0.CO;2-O (Pubitemid 26195721)
29. GE Alexander MR DeLong PL Strick 1986 Parallel organization of functionally segregated circuits linking basal ganglia and cortex Ann Rev Neurosci 9 357 381 10.1146/annurev.ne.09.030186.002041 1:STN:280: DyaL283htlKksw%3D%3D 3085570
30. GE Alexander MD Crutcher 1990 Functional architecture of basal ganglia circuits: neural substrates of parallel processing Trends Neurosci 13 266 271 10.1016/0166-2236(90)90107-L 1:CAS:528:DyaK3MXjs1Snuw%3D%3D 1695401
31. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988.
32. S Hirano K Asanuma Y Ma C Tang A Feigin V Dhawan, et al. 2008 Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease J Neurosci 28 4201 4209 10.1523/JNEUROSCI.0582- 08.2008 1:CAS:528:DC%2BD1cXltVOnurc%3D 18417699
33. SA Eshuis RP Maguire KL Leenders S Jonkman PL Jager 2006 Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease Eur J Nucl Med Mol Imaging 33 200 209 10.1007/s00259-005-1904-y 1:STN:280:DC%2BD28%2FlsV2iuw%3D%3D 16228235 (Pubitemid 43152888)
34. V Kaasinen RP Maguire HP Hundemer KL Leenders 2006 Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease J Neurol 253 340 348 10.1007/s00415-005-0993-7 1:STN:280:DC%2BD287lsVWhtQ%3D%3D 16222426
35. HTS Benamer J Patterson DJ Wyper DM Hadley GJ Macphee DG Grosset 2000 Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake Mov Disord 15 692 698 10.1002/1531-8257(200007)15:4<692::AID- MDS1014>3.0.CO;2-V 1:STN:280:DC%2BD3M%2FotlWqsg%3D%3D 10928580 (Pubitemid 30479622)
36. GE Alexander K Chen P Pietrini SI Rapoport EM Reiman 2002 Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies Am J Psychiatry 159 738 745 10.1176/appi.ajp.159.5.738 11986126 (Pubitemid 34465046)
37. R Albin AB Young JB Penny 1989 The functional anatomy of basal ganglia disorders Trends Neurosci 12 366 375 10.1016/0166-2236(89)90074-X 1:STN:280:DyaK3c%2FltVGjsA%3D%3D 2479133
38. JA Obeso MC Rodriguez-Oroz M Rodriguez JL Lanciego J Artieda N Gonzao, et al. 2000 Pathophysiology of the basal ganglia in Parkinson's disease Trens Neurosci 2 S8 S19 10.1016/S1471-1931(00)00028-8
39. SE Leh A Ptito MM Chakravarty AP Strafella 2007 Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study Neurosci Lett 419 113 118 10.1016/j.neulet.2007.04.049 1:CAS:528: DC%2BD2sXltF2qu7w%3D 17485168 (Pubitemid 46719662)
40. JA Obeso C Marin C Rodriguez-Oroz J Blesa B Benitez-Temino J Mena-Segovia, et al. 2008 The basal ganglia in Parkinson's disease: current concepts and unexplained observations Ann Neurol 64 S30 S46 19127584
41. C Lozza RM Marié JC Baron 2002 The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson's disease Neuroimage 17 688 699 10.1016/S1053-8119(02)91245-0 1:STN:280:DC%2BD38nitV2qsA%3D%3D 12377144 (Pubitemid 35317004)
42. T Eckert C Tang D Eidelberg 2007 Assessment of the progression of Parkinson's disease: a metabolic network approach Lancet Neurol 6 926 932 10.1016/S1474-4422(07)70245-4 17884682 (Pubitemid 47405003)
43. M Carbon D Eidelberg 2002 Modulation of regional brain function by deep brain stimulation: studies with positron emission tomography Curr Opin Neurol 15 451 455 10.1097/00019052-200208000-00008 12151842 (Pubitemid 34828122)
44. C Lozza JC Baron D Eidelberg MJ Mentis M Carbon RM Marié 2004 Executive processes in Parkinson's disease: FDG-PET and network analysis Hum Brain Mapp 22 236 245 10.1002/hbm.20033 15195290 (Pubitemid 38891002)
45. 15 O-, and FDG-PET. Int J Biomed Imag 2006;1-13.
46. AL Brownell K Canales YI Chen BG Jenkins C Owen E Livni M Yu F Cicchetti R Sanchez-Pernaute O Isacson 2003 Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model Neuroimage. 20 2 1064 1075 10.1016/S1053-8119(03)00348-3 14568476 (Pubitemid 37268125)
47. W Meissner C Guigoni L Cirilli M Garret BH Bioulac CE Gross E Bezard A Benazzouz 2007 Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease Eur J Neurosci. 25 5 1492 1500 10.1111/j.1460-9568.2007.05406.x 17425575 (Pubitemid 46568772)
48. AA Utter MA Basso 2008 The basal ganglia: an overview of circuits and function Neurosci Biobehav Rev 32 3 333 342 10.1016/j.neubiorev.2006.11.003 17202023 (Pubitemid 351192948)
49. H Braak U Rub C Schultz K Del Tredici 2006 Vulnerability of cortical neurons to Alzheimer's and Parkinson's disease J Alzheimers Dis 9 35 44 1:CAS:528:DC%2BD28XotFKktrs%3D 16914843
50. Biomarkers Definition Working Group 2001 Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 89 95 10.1067/mcp.2001.113989 (Pubitemid 32225406)